I'm up to page 16 but it seems like it took 10 tests to get a result they could rely on and this is the reason for the delay, although they would have been able to look at the age of the person on the sample bottle and other information and realised whose sample it was and what the implications of this being delayed would be.
I don't understand the difficulties they had with the tests. I'm sure it will be talked about in the weeks and months ahead, I'm sure it's all Kamila's fault of course...
The Stockholm laboratory was closed for the period from December 30, 2021 to January 10, 2022 inclusive.
On January 11, 2022, the Stockholm laboratory recorded that ITP sample A tested positive for the drug trimetazidine (or “TMZ”). (It is common knowledge that TMZ is included in section 4.4 of the 2021 Prohibited Substances List and is classified as a non-specific substance.)
On January 12, 2022, the Stockholm laboratory took another aliquot of Sample A, designated "202107432A-6", for the purpose of estimating specific gravity.
On January 12, 2022, the Stockholm laboratory began the confirmation procedure for sample A. An aliquot designated “202107432A-7” was taken for this purpose. (The Parties and the Panel use the term “Confirmation Procedure” as defined in the ISL as follows: “An analytical testing procedure whose purpose is to confirm the presence and/or, where applicable, confirm the concentration/rate/score and/or establish the origin (exogenous or endogenous) of one or more specified Prohibited Substances, metabolites of a Prohibited Substance, or marker(s) of Use of a Prohibited Substance or Prohibited Method in a Sample.").
On January 17, 2022, Stockholm Laboratory rejected confirmation procedure number 202107432A-7 due to “unsatisfactory quality control results.” According to the Stockholm laboratory, this was "due to poor chromatographic peak shape of the reference material, resulting in unsymmetrical chromatographic peaks."
On January 19, 2022, the Stockholm laboratory took another aliquot of sample A, designated “202107432A-8,” and began the second confirmation procedure. It was also rejected due to "unsatisfactory quality control results."
On the same day, January 19, 2022, the Stockholm laboratory took another aliquot from Sample A, designated "202107432A-9", and began the confirmation procedure for this aliquot on the same day.
On January 20, 2022, confirmation procedure number 202107432A-9 “was also rejected due to “unsatisfactory quality control results, specifically an unsatisfactory quality control chromatographic profile.”
Around the same day, January 20, 2022, the Stockholm laboratory decided to "develop a new analytical method for the validation procedure, since the repeated violation of the peak shape was unexpected since the current analytical method was found fit for purpose after validation."
Between January 31 and February 3, 2022, Stockholm Laboratory prepared a document entitled “Validation Plan for Trimetazidine, Lomerizine and Metabolites by UHPLC-HRMS Validation Plan” (“Validation Plan”). (UHPLC-HRMS stands for Ultra-High Resolution Liquid Chromatography-High Resolution Mass Spectrometry). The validation plan specifies the means by which “a method for the qualitative confirmation of prohibited non-threshold compounds... shall be validated. Validation is carried out in accordance with [ISL], section "Validation method for non-threshold substances", which states that "method validation must demonstrate that the method is 'fit for purpose'."
On February 4, 2022, another aliquot was taken from sample A, designated 202107432A-10.
On 7 February 2022, the Stockholm Laboratory published the “Trimetazidine, Lomerizine and Metabolite, UHPLC-HRMS, Qualitative Validation, Validation Report” (“Validation Report”). In a validation report, the Stockholm laboratory concluded that the proposed method was “fit for purpose.”
On the same date, 7 February 2022, Stockholm Laboratory completed confirmation of reference number 202107432A-10 and (i) recorded the result in Stockholm Laboratory's LIMS and (ii) submitted to WADA's Anti-Doping Administration and Management System (“ADAMS”). ) "Test Report" stating that the test result was an "Adverse Analytical Finding" (or "AAF") for Sample A for "S4. Hormone and metabolite modulators/trimetazidine.”
On February 8, 2022, the Stockholm laboratory provided RUSADA (in response to a request for the concentration level detected by the Stockholm laboratory) with an approximate concentration of 2.1 ng/ml (or 0.0021 mg/l). This was provided for in the stated qualifications, that there were no requirements for
CAS 2023/A/9451 - CAS 2023/A/9455 - CAS 2023/A/9456 – page 10 Report the concentration of non-threshold substances (such as TMZ) and that “the laboratory used a method that was developed for qualitative purposes and, with the exception of establishing that the mentioned substance is present in the Sample in a concentration exceeding the limit of the identification method, determining the absolute concentration of the analyte in the Sample goes beyond the intended purpose.”